Why patient deaths don’t necessarily scuttle Global Blood’s chances for voxelotor’s clinical success.
ASH data offers insight into Gilead Sciences’ lymphoma drug Yescarta; Maxim’s Jason McCarth weighs in.
The annual meeting for the American Society of Hematology (ASH) has just kicked off. Running …
Immu-132 continues to have strong efficacy in centrally-reviewed data at SABCS, says Cowen’s Phil Nadeau.
Guggenheim’s Rohit Vanjani puts a price tag on Revance Therapeutics.
With the tremendous focus on the opioid crisis, Raymond James’ Elliot Wilbur sees exciting potential for Adamis.
The Good: Oppenheimer Sees Celsion Corporation Shares Soaring About 180% Over 12 Months It can …
Cantor’s Elemer Piros waits for pass-through reimbursement to be address, before joining the ‘Omeros party’.
Brexanolone poised to become first approved therapy for PPD, says Needham’s Danielle Brill.
The market has divided itself into two camps. The bulls argue that the worst is …